#1 Clinical Trials Search in Europe

Oritavancin

Oritavancin is an antibiotic being studied in clinical trials for the treatment of various bacterial infections, particularly those caused by gram-positive bacteria. This article summarizes key findings from recent clinical trials investigating the safety, efficacy, and potential applications of oritavancin in different patient populations and infection types.

Table of Contents

What is Oritavancin?

Oritavancin, also known by its brand names Orbactiv® and KIMYRSA™, is an antibiotic medication used to treat certain bacterial infections[1]. It belongs to a class of antibiotics called lipoglycopeptides, which work by preventing bacteria from building their cell walls, ultimately leading to their death[3].

This medication is particularly effective against Gram-positive bacteria, which are a specific type of bacteria that can cause serious infections[1]. Oritavancin is unique because it can be given as a single dose or infrequent doses, which may make it more convenient for patients compared to other antibiotics that require daily administration[8].

What Conditions Does Oritavancin Treat?

Oritavancin is primarily used to treat the following conditions:

  • Acute Bacterial Skin and Skin Structure Infections (ABSSSIs): These are serious skin infections that can involve deeper layers of skin and surrounding tissues[2].
  • Complicated Skin and Skin Structure Infections (cSSSI): These are more severe skin infections that may require surgical intervention[8].
  • Gram-Positive Bacterial Infections: This includes infections caused by bacteria such as Staphylococcus aureus (including methicillin-resistant strains known as MRSA) and Streptococcus species[1][3].

In some clinical trials, oritavancin is also being studied for its potential use in treating more serious infections such as:

  • Bacteremia: A condition where bacteria are present in the bloodstream[7].
  • Endocarditis: An infection of the inner lining of the heart chambers and valves[7].
  • Osteomyelitis: An infection of the bone[5].
  • Septic Arthritis: An infection in a joint[5].

How is Oritavancin Administered?

Oritavancin is administered as an intravenous (IV) infusion, which means it’s given directly into a vein. The typical dose for adults is 1200 mg given as a single dose over 3 hours[4]. This single-dose regimen is one of the unique features of oritavancin, as it can complete an entire course of antibiotic treatment in just one administration.

In some cases, especially for more serious infections, multiple doses may be given. For example:

  • A weekly dose of 1200 mg for several weeks[5].
  • An initial dose followed by an optional second dose on day 5, depending on the patient’s response[8].

The exact dosing regimen will be determined by your healthcare provider based on your specific condition and other factors.

Oritavancin in Clinical Trials

Oritavancin has been and continues to be studied in various clinical trials to better understand its effectiveness, safety, and potential new uses. Some notable areas of research include:

  • Pediatric Use: Studies are being conducted to determine the appropriate dosing and safety of oritavancin in children and adolescents[2][3].
  • Use in Opioid Users: Researchers are investigating the potential of oritavancin to treat infections in people with opioid use disorder, as this population is at higher risk for certain types of infections[5][7].
  • Real-World Effectiveness: Studies are being conducted to evaluate how well oritavancin works in actual clinical practice, outside of controlled research settings[1].

Safety and Side Effects

Like all medications, oritavancin can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Vomiting
  • Diarrhea
  • Dizziness
  • Itching
  • Reactions at the infusion site (such as pain or redness)[9]

More serious side effects are rare but can occur. These may include severe allergic reactions or effects on blood clotting tests[4]. It’s important to discuss all potential side effects with your healthcare provider before starting treatment.

Special Considerations

There are a few special considerations to keep in mind with oritavancin:

  • Effect on Blood Tests: Oritavancin can interfere with certain blood clotting tests for up to 5 days after administration. This is important to know if you need any blood tests or surgical procedures during this time[4].
  • Interaction with Warfarin: If you’re taking the blood thinner warfarin, your doctor will need to monitor you closely as oritavancin can affect how warfarin works in your body[9][10].
  • Pregnancy and Breastfeeding: The safety of oritavancin during pregnancy and breastfeeding is not well established. Always inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.

Remember, oritavancin is a prescription medication and should only be used under the guidance of a healthcare professional. Always follow your doctor’s instructions and report any unusual symptoms or side effects promptly.

Aspect Details
Primary Use Treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by gram-positive bacteria
Dosing Single 1200 mg IV infusion over 3 hours; some trials exploring weekly dosing for certain infections
Patient Populations Adults, pediatrics (studies ongoing), patients with opioid use disorder
Key Advantages Single-dose treatment, potential for reduced hospital stays, convenient option for patients with opioid use disorder
Safety Considerations May affect coagulation test results, being studied in patients on warfarin therapy
Ongoing Research Pediatric dosing, use in various systemic infections (bacteremia, endocarditis, osteomyelitis)

FAQ

  • What is oritavancin used to treat? Oritavancin is primarily used to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by gram-positive bacteria. It is also being studied for other infections like bacteremia, endocarditis, and osteomyelitis.
  • How is oritavancin administered? Oritavancin is typically administered as a single intravenous (IV) dose of 1200 mg, infused over 3 hours. Some trials are exploring different dosing regimens, including weekly doses for certain infections.
  • What are the main advantages of oritavancin? Oritavancin offers several advantages, including the potential for single-dose treatment, which can improve patient compliance and reduce hospital stays. It is also being studied for use in patients with opioid use disorder, potentially offering a more convenient treatment option.
  • Are there any special considerations when using oritavancin? Oritavancin can artificially prolong certain coagulation tests, so caution is needed when interpreting these results. It's also being studied in patients on warfarin therapy to ensure safety in this population.
  • Is oritavancin safe for children? Clinical trials are ongoing to evaluate the safety, efficacy, and appropriate dosing of oritavancin in pediatric patients. Current studies include children from birth to 18 years old with various bacterial infections.

Ongoing Clinical Trials on Oritavancin

  • Study of single-dose oritavancin safety and tolerability in children with acute bacterial skin and skin structure infections

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Greece Latvia Lithuania Poland Portugal +2

Glossary

  • Acute bacterial skin and skin structure infections (ABSSSIs): Serious skin infections caused by bacteria, including conditions like cellulitis, wound infections, and abscesses.
  • Gram-positive bacteria: A class of bacteria that retain crystal violet dye when stained, including many common pathogens like Staphylococcus aureus and Streptococcus species.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Bacteremia: The presence of bacteria in the bloodstream.
  • Endocarditis: An infection of the inner lining of the heart chambers and valves.
  • Osteomyelitis: An infection of the bone or bone marrow.
  • Coagulation tests: Laboratory tests that measure the blood's ability to clot, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT).
  • Warfarin: An anticoagulant medication used to prevent blood clots.
  • Adverse event (AE): Any undesirable experience associated with the use of a medical product in a patient.
  • Serious adverse event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.

References

  1. https://clinicaltrials.gov/study/NCT03159403
  2. https://clinicaltrials.gov/study/NCT05599295
  3. https://clinicaltrials.gov/study/NCT02134301
  4. https://clinicaltrials.gov/study/NCT02357524
  5. https://clinicaltrials.gov/study/NCT05521880
  6. https://clinicaltrials.gov/study/NCT02471690
  7. https://clinicaltrials.gov/study/NCT03761953
  8. https://clinicaltrials.gov/study/NCT00514527
  9. https://clinicaltrials.gov/study/NCT02452918
  10. https://clinicaltrials.gov/study/NCT02340988